In solid tumors and lymphomas, the neutrophil/lymphocyte (N/L) ratio at diagnosis has been shown to be a prognostic factor. The aim of our study was to validate the originally reported N/L ratio cut-point of 3.5 in patients with diffuse large B-cell lymphoma (DLBCL) registered in an Italian real-life database. The prognostic role of the N/L ratio at diagnosis on event-free survival (EFS) and overall survival (OS) was assessed in 505 patients with DLBCL. Patients with an N/L ratio <3.5 (n = 249) had a 4-year EFS probability of 76% and OS probability of 86%, significantly higher than the 4 year EFS rate of 48% and OS rate of 64% in patients with N/L ratio ≥3.5 (n = 256, both p<.0001). The N/L ratio was an independent prognostic factor in the multivariate analysis including the IPI score, and could separate patients with a low/intermediate risk IPI (IPI <3).

Annibali, O., Hohaus, S., Marchesi, F., Cantonetti, M., Di Rocco, A., Tomarchio, V., Di Napoli, A., Pelliccia, S., Battistini, R., Anticoli Borza, P., Abruzzese, E., Cenfra, N., Andriani, A., Tesei, C., Alma, E., Palombi, F., Pupo, L., Petrucci, L., Becilli, M., Maiolo, E., Bellesi, S., Cuccaro, A., D'Alo', F., Cox, M. C., (Abstract) The neutrophil/lymphocyte ratio ≥3.5 is a prognostic marker in diffuse large B-cell lymphoma: a retrospective analysis from the database of the Italian regional network ‘Rete Ematologica del Lazio per i Linfomi’ (RELLI), <<LEUKEMIA & LYMPHOMA>>, 2019; (1): 1-9-9. [doi:10.1080/10428194.2019.1633628] [http://hdl.handle.net/10807/141174]

The neutrophil/lymphocyte ratio ≥3.5 is a prognostic marker in diffuse large B-cell lymphoma: a retrospective analysis from the database of the Italian regional network ‘Rete Ematologica del Lazio per i Linfomi’ (RELLI)

Hohaus, Stefan;Alma, Eleonora;Bellesi, Silvia;Cuccaro, Annarosa;D'Alo', Francesco;
2019

Abstract

In solid tumors and lymphomas, the neutrophil/lymphocyte (N/L) ratio at diagnosis has been shown to be a prognostic factor. The aim of our study was to validate the originally reported N/L ratio cut-point of 3.5 in patients with diffuse large B-cell lymphoma (DLBCL) registered in an Italian real-life database. The prognostic role of the N/L ratio at diagnosis on event-free survival (EFS) and overall survival (OS) was assessed in 505 patients with DLBCL. Patients with an N/L ratio <3.5 (n = 249) had a 4-year EFS probability of 76% and OS probability of 86%, significantly higher than the 4 year EFS rate of 48% and OS rate of 64% in patients with N/L ratio ≥3.5 (n = 256, both p<.0001). The N/L ratio was an independent prognostic factor in the multivariate analysis including the IPI score, and could separate patients with a low/intermediate risk IPI (IPI <3).
2019
Inglese
Annibali, O., Hohaus, S., Marchesi, F., Cantonetti, M., Di Rocco, A., Tomarchio, V., Di Napoli, A., Pelliccia, S., Battistini, R., Anticoli Borza, P., Abruzzese, E., Cenfra, N., Andriani, A., Tesei, C., Alma, E., Palombi, F., Pupo, L., Petrucci, L., Becilli, M., Maiolo, E., Bellesi, S., Cuccaro, A., D'Alo', F., Cox, M. C., (Abstract) The neutrophil/lymphocyte ratio ≥3.5 is a prognostic marker in diffuse large B-cell lymphoma: a retrospective analysis from the database of the Italian regional network ‘Rete Ematologica del Lazio per i Linfomi’ (RELLI), <<LEUKEMIA & LYMPHOMA>>, 2019; (1): 1-9-9. [doi:10.1080/10428194.2019.1633628] [http://hdl.handle.net/10807/141174]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/141174
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 10
  • ???jsp.display-item.citation.isi??? 9
social impact